文献速递湿疹皮炎与荨麻疹

普美替尼3%凝胶治疗轻中度特应性皮炎IIb期试验

Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial.
PubMed 文献 · Br J Dermatol · 2026-01-01

这项多中心随机双盲安慰剂对照IIb期试验纳入139例轻中度特应性皮炎成人患者,按1:1:1随机分配至普美替尼3%凝胶每日两次组、每日一次组或安慰剂组治疗8周。结果显示,每日两次组EASI评分较基线变化百分比为-83.6%,优于每日一次组(-44.0%)和安慰剂组(-22.0%),且安全性与安慰剂相似。

要点

  • 普美替尼3%凝胶每日两次或一次均显著优于安慰剂,每日两次效果更佳。
  • 每日两次组EASI评分较基线改善-83.6%,每日一次组-44.0%,安慰剂组-22.0%。
  • 不良事件发生率普美替尼组与安慰剂组均为48%,耐受性良好。

核心结论

  • 普美替尼3%凝胶治疗成人轻中度特应性皮炎有效且安全,每日两次方案疗效优于每日一次。

研究设计与样本

  • 多中心随机双盲平行安慰剂对照IIb期临床试验,纳入139例轻中度特应性皮炎成人患者,按1:1:1随机分配至普美替尼3%凝胶每日两次组(n=47)、每日一次组(n=46)或安慰剂组(n=46),治疗8周。

主要发现

  • 第8周时,每日两次组、每日一次组和安慰剂组的EASI评分较基线变化百分比分别为-83.6%、-44.0%和-22.0%。
  • 两种普美替尼治疗方案均显著优于安慰剂(P < 0.006),且每日两次方案优于每日一次方案(P < 0.001)。
  • 其他疗效终点(IGA 0/1、EASI 50、EASI 75、EASI 90及生活质量改善)在普美替尼组均优于安慰剂组,每日两次方案 consistently 表现更佳。
  • 不良事件发生率普美替尼组和安慰剂组均为48%,安全性特征总体相似,治疗耐受性良好。
  • 8周治疗期间平均血浆药物浓度较低(范围38-104 pg mL-1)。

关键数值与推荐

  • 主要疗效终点为第8周EASI评分较基线变化百分比。
  • 第8周IGA评分0或1(较基线改善≥2分)的参与者百分比、EASI 50、EASI 75、EASI 90及生活质量改善为其他评估指标。

临床怎么用

  • 普美替尼3%凝胶每日两次可作为成人轻中度特应性皮炎的新型局部JAK抑制剂治疗选择。
  • 每日两次方案较每日一次显示出更优疗效,且未增加额外风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a phase IIb clinical trial of pumecitinib 3% gel (PG-011), a novel selective Janus kinase (JAK)1/2 inhibitor, applied topically to treat mild-to-moderate atopic dermatitis (AD). OBJECTIVES: To assess pumecitinib 3% gel for its efficacy and safety in treating adult patients with mild-to-moderate AD, and to determine the optimal treatment regimen. METHODS: In this study, 139 participants with mild-to-moderate AD were randomized 1 : 1 : 1 to pumecitinib 3% gel twice daily (n = 47), pumecitinib 3% gel once daily (n = 46) and placebo (n = 46) for 8 weeks of treatment. Percentage change in Eczema Area and Severity Index (EASI) score from baseline to week 8 was the primary efficacy endpoint. The percentage of participants with an Investigator's Global Assessment score of 0 or 1 (≥ 2-point improvement from baseline) at week 8, the proportion of participants attaining ≥ 50% improvement in EASI (EASI 50), ≥ 75% improvement in EASI (EASI 75) and ≥ 90% improvement in EASI (EASI 90) at week 8, and improvement in quality of life were also evaluated. Safety, local tolerability and some pharmacokinetics were monitored. RESULTS: At week 8, the percentage change from baseline in EASI score in the pumecitinib 3% gel twice daily, pumecitinib 3% gel once daily and placebo groups was -83.6%, -44.0% and -22.0%, respectively. Both pumecitinib treatment regimens showed a significantly greater effect compared with placebo (P < 0.006) and the pumecitinib 3% gel twice-daily regimen had a greater effect than once-daily treatment (P < 0.001). Other efficacy endpoints were also improved in participants in the pumecitinib groups vs. those in the placebo group, and pumecitinib 3% gel twice daily consistently exhibited better efficacy than the once-daily treatment. With regard to safety, the rate of adverse events in the pumecitinib and placebo groups was 48% and 48%, respectively. Safety profiles were generally similar between the pumecitinib and placebo groups, and treatment was well tolerated. Mean plasma drug concentrations were low (range 38-104 pg mL-1) over the 8-week treatment period. CONCLUSIONS: Pumecitinib 3% gel showed good efficacy and safety profiles in the treatment of adults with mild-to-moderate AD. The pumecitinib 3% twice-daily treatment regimen showed greater efficacy than the once-daily regimen in treating mild-to-moderate AD. Pumecitinib 3% gel was well tolerated and generated low systemic drug exposure when used topically. It may be a new choice of topical JAK inhibitor to treat mild-to-moderate AD. Atopic dermatitis is a long-term inflammatory skin disease. It is also known as eczema. It mainly affects children and adolescents. The disease is associated with itching and skin rashes. It can have a severe impact on people’s quality of life. Only a few medicines that can be applied to the skin are available to treat it. A medicine called ‘pumecitinib’ is well tolerated when applied to the skin. It passes through the skin and into the bloodstream, and is quickly cleared from the body. In this study, we wanted to find out if pumecitinib gel used once or twice daily for 8 weeks worked well and was safe for treating of mild-to-moderate disease in adults. Patients with the disease were split into three groups. One group used the gel once daily, the second group used it twice daily and the third group was given a gel with no medicine (a ‘placebo’) to apply. We found that the gel containing the medicine used once or twice daily was much more effective than the placebo. Patients who applied the medicated gel twice a day showed a significant difference in improvement after 1 week of treatment. Overall, using the medicated gel twice daily was more effective than using it once a day. Side effects were mild and none led to people stopping the treatment. In conclusion, pumecitinib gel works well and is safe to use in the treatment of mild-to-moderate eczema. Our results suggest that using the gel twice a day is more beneficial than using it once a day. There are no extra risks in using it twice a day. Pumecitinib gel may be an innovative new treatment for eczema.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Wang M, Zhang L, et al. Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial. Br J Dermatol. 2026. PMID: 40973120. doi:10.1093/bjd/ljaf363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。